Targeting small airways in asthma: Improvement in clinical benefit?

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Targeting small airways in asthma: Improvement in clinical benefit? / Ulrik, Charlotte Suppli; Lange, Peter.

In: Clinical Respiratory Journal, 2010.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Ulrik, CS & Lange, P 2010, 'Targeting small airways in asthma: Improvement in clinical benefit?', Clinical Respiratory Journal. https://doi.org/10.1111/j.1752-699X.2010.00235.x

APA

Ulrik, C. S., & Lange, P. (2010). Targeting small airways in asthma: Improvement in clinical benefit? Clinical Respiratory Journal. https://doi.org/10.1111/j.1752-699X.2010.00235.x

Vancouver

Ulrik CS, Lange P. Targeting small airways in asthma: Improvement in clinical benefit? Clinical Respiratory Journal. 2010. https://doi.org/10.1111/j.1752-699X.2010.00235.x

Author

Ulrik, Charlotte Suppli ; Lange, Peter. / Targeting small airways in asthma: Improvement in clinical benefit?. In: Clinical Respiratory Journal. 2010.

Bibtex

@article{eb18f0538c8643ad8e64d499f389c5f5,
title = "Targeting small airways in asthma: Improvement in clinical benefit?",
abstract = "Background and Aim: Disease control is not achieved in a substantial proportion of patients with asthma. Recent advances in aerosol formulations and delivery devices may offer more effective therapy. This review will focus on the importance and potential clinical benefit of targeting the lung periphery in adult asthma by means of ultrafine aerosols. Results: Ultrafine formulations of inhaled corticosteroids have improved lung deposition up to at least 50 %, primarily in the peripheral airways. Ultrafine formulations of ICS provide equivalent asthma control to non-ultrafine ICS at approximately half the daily dose with no increased risk of systemic effects. Clinical studies of adults with asthma have shown a greater effect of ultrafine ICS, compared with non-ultrafine ICS, on quality of life, small airway patency, and markers of pulmonary and systemic inflammation, but no difference with regard to conventional clinical indices of lung function and asthma control. Conclusions: Asthma patients treated with ultrafine ICS, compared with non-ultrafine ICS, have at least similar chance of achieving asthma control at a lower daily dose. Further clinical studies are needed to explore whether treatment with ultrafine formulations of ICS will change the natural history of asthma and prevent airway remodelling in both the large and small airways.",
author = "Ulrik, {Charlotte Suppli} and Peter Lange",
note = "{\textcopyright} 2010 Blackwell Publishing Ltd.",
year = "2010",
doi = "http://dx.doi.org/10.1111/j.1752-699X.2010.00235.x",
language = "English",
journal = "Clinical Respiratory Journal",
issn = "1752-6981",
publisher = "Wiley-Blackwell",

}

RIS

TY - JOUR

T1 - Targeting small airways in asthma: Improvement in clinical benefit?

AU - Ulrik, Charlotte Suppli

AU - Lange, Peter

N1 - © 2010 Blackwell Publishing Ltd.

PY - 2010

Y1 - 2010

N2 - Background and Aim: Disease control is not achieved in a substantial proportion of patients with asthma. Recent advances in aerosol formulations and delivery devices may offer more effective therapy. This review will focus on the importance and potential clinical benefit of targeting the lung periphery in adult asthma by means of ultrafine aerosols. Results: Ultrafine formulations of inhaled corticosteroids have improved lung deposition up to at least 50 %, primarily in the peripheral airways. Ultrafine formulations of ICS provide equivalent asthma control to non-ultrafine ICS at approximately half the daily dose with no increased risk of systemic effects. Clinical studies of adults with asthma have shown a greater effect of ultrafine ICS, compared with non-ultrafine ICS, on quality of life, small airway patency, and markers of pulmonary and systemic inflammation, but no difference with regard to conventional clinical indices of lung function and asthma control. Conclusions: Asthma patients treated with ultrafine ICS, compared with non-ultrafine ICS, have at least similar chance of achieving asthma control at a lower daily dose. Further clinical studies are needed to explore whether treatment with ultrafine formulations of ICS will change the natural history of asthma and prevent airway remodelling in both the large and small airways.

AB - Background and Aim: Disease control is not achieved in a substantial proportion of patients with asthma. Recent advances in aerosol formulations and delivery devices may offer more effective therapy. This review will focus on the importance and potential clinical benefit of targeting the lung periphery in adult asthma by means of ultrafine aerosols. Results: Ultrafine formulations of inhaled corticosteroids have improved lung deposition up to at least 50 %, primarily in the peripheral airways. Ultrafine formulations of ICS provide equivalent asthma control to non-ultrafine ICS at approximately half the daily dose with no increased risk of systemic effects. Clinical studies of adults with asthma have shown a greater effect of ultrafine ICS, compared with non-ultrafine ICS, on quality of life, small airway patency, and markers of pulmonary and systemic inflammation, but no difference with regard to conventional clinical indices of lung function and asthma control. Conclusions: Asthma patients treated with ultrafine ICS, compared with non-ultrafine ICS, have at least similar chance of achieving asthma control at a lower daily dose. Further clinical studies are needed to explore whether treatment with ultrafine formulations of ICS will change the natural history of asthma and prevent airway remodelling in both the large and small airways.

U2 - http://dx.doi.org/10.1111/j.1752-699X.2010.00235.x

DO - http://dx.doi.org/10.1111/j.1752-699X.2010.00235.x

M3 - Journal article

JO - Clinical Respiratory Journal

JF - Clinical Respiratory Journal

SN - 1752-6981

ER -

ID: 34121569